- Home
- USIO vs LTRN Comparison
USIO vs LTRN Comparison
Compare USIO & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- LTRN
- Stock Information
- Founded
- USIO 1998
- LTRN 2013
- Country
- USIO United States
- LTRN United States
- Employees
- USIO 111
- LTRN N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- LTRN Health Care
- Exchange
- USIO Nasdaq
- LTRN Nasdaq
- Market Cap
- USIO 47.7M
- LTRN 36.0M
- IPO Year
- USIO N/A
- LTRN 2020
- Fundamental
- Price
- USIO $1.78
- LTRN $3.95
- Analyst Decision
- USIO Strong Buy
- LTRN Strong Buy
- Analyst Count
- USIO 1
- LTRN 1
- Target Price
- USIO $4.00
- LTRN $25.00
- AVG Volume (30 Days)
- USIO 100.0K
- LTRN 541.6K
- Earning Date
- USIO 08-06-2025
- LTRN 08-07-2025
- Dividend Yield
- USIO N/A
- LTRN N/A
- EPS Growth
- USIO N/A
- LTRN N/A
- EPS
- USIO 0.12
- LTRN N/A
- Revenue
- USIO $83,970,504.00
- LTRN N/A
- Revenue This Year
- USIO $16.02
- LTRN N/A
- Revenue Next Year
- USIO $13.24
- LTRN N/A
- P/E Ratio
- USIO $14.96
- LTRN N/A
- Revenue Growth
- USIO 0.46
- LTRN N/A
- 52 Week Low
- USIO $1.24
- LTRN $2.55
- 52 Week High
- USIO $2.92
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- USIO 62.02
- LTRN 56.69
- Support Level
- USIO $1.72
- LTRN $3.84
- Resistance Level
- USIO $1.83
- LTRN $4.43
- Average True Range (ATR)
- USIO 0.11
- LTRN 0.46
- MACD
- USIO -0.00
- LTRN 0.02
- Stochastic Oscillator
- USIO 56.72
- LTRN 63.59
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.